SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to...
Hence then, the article about daan biotherapeutics signs antibody exclusive licensing agreement with ligachem biosciences for adc antibody drug conjugate therapeutic development was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development )
Also on site :